

**REMARKS**

The communication mailed on April 3<sup>rd</sup> comprises a restriction requirement. The Examiner is restricting the claims as filed into three (3) groups, and also requesting for each group an election of species.

Applicants, through their attorney, hereby elect for further prosecution at this time the group designated by the examiner as Group I, drawn to pharmaceutical combinations classified in class 514, subclass 418. This group includes Claims 1 through 18.

For a single antagonist of at least one receptor selected from VEGFR, PDGFR, FGFR, etc., applicants elect compound T of Claim 10, which is also the compound of Claim 11 and a specific salt form is claimed in Claim 12.

For a single chemotherapeutic agent, applicants elect the compound of Claim 16, which compound is a dual antagonist of epidermal growth factor (EGF) receptor and of human epidermal growth factor of type 2 (ITE type 2) receptor. A salt of such compound is claimed in Claim 17.

For the Examiner's reference, the specific combination has been tested and the results reported starting on page 68 of the specification as filed.

The election is without traverse.

Application No. 10/830,147  
Response to Office Action of April 3, 2007  
Response dated July 30, 2007

Accordingly, Applicants respectfully submit that this application is now in condition for early examination. If any points remain at issue which can best be resolved by way of telephone or personal interview, the Examiner is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,

/Mary-Ellen M. Devlin/  
Mary-Ellen M. Devlin  
Attorney for Applicants  
Reg. No. 27,928

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4866  
Fax: (203) 798-4408

July 30, 2007